Cogstate Ltd (ASX.CGS) is pleased to announce the appointment of Dr. Richard Mohs as a non-executive director. Dr. Mohs retired from Eli Lilly in 2015, where he held several leadership positions including Vice President for Neuroscience Early Clinical Development and Leader of the Global Alzheimer’s Drug Development Team. Before joining Eli Lilly in 2002, Richard spent 23 years with the Mount Sinai School of Medicine in NY where he was Professor in the Department of Psychiatry and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Center.
Dr. Mohs received a Ph.D. in psychology from Stanford University and completed postdoctoral training in pharmacology at the Stanford University Medical School. He is the author or co-author of over 350 scientific papers, including those describing clinical trials that lead to the approval, in the US and other countries, of cholinergic drug treatments for Alzheimer’s disease.
Dr. Mohs is currently Chief Scientific Officer for the Global Alzheimer’s Platform (GAP) Foundation, a patient-centered, non-profit organization devoted to enhancing the speed and quality with which new treatments for Alzheimer’s disease are developed. Richard also serves as a consultant to academic institutions, foundations and biopharmaceutical companies, and is a member of the Board of Governors for the Alzheimer’s Drug Discovery Foundation.
“I am very pleased that Dr. Mohs has joined the board” commented Mr. Martyn Myer AO, Chairman of Cogstate Limited. “His scientific leadership in neuroscience drug development and his extensive experience across public and private sectors will bring invaluable expertise to the Cogstate board. His appointment continues the enhancement of Cogstate’s leadership that includes the appointment of George Hunnewell and Frank Cheng in November 2016”.
Cogstate will seek to further strengthen its Board in the coming weeks, when it expects to be able to announce the addition of another independent non-executive director.
